Kyverna Therapeutics Inc. (KYTX) stock has reached a new 52-week low, trading at $2.78, down 10.4% in the past week alone, as the biotechnology firm faces a challenging market environment. According ...
The Food and Drug Administration (FDA) approved a new drug to treat a disorder causing the growth of non-cancerous tumors on ...
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...
In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
Kyverna Therapeutics, Inc. (KYTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want ...
The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. . Shareholders who purchased shares ...
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results